Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
GlobeNewswire
*Ad hoc announcement pursuant to Art. 53 LR*
· *Q1 net sales grew +11% (cc*^*1**, +10% USD) with core operating income..
*Ad hoc announcement pursuant to Art. 53 LR*
· *Q1 net sales grew +11% (cc*^*1**, +10% USD) with core operating income..
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Cardiac Marker Global Market Report 2024" report has been added to *..
· *Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented..